In plaque psoriasis, the most common form of psoriasis ... but many known triggers are factors that promote systemic inflammation or widespread suppression of the immune system.

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

It differs from other types of psoriasis in its specific clinical presentation, severity, and underlying causes. GPP involves the widespread formation of pustules, which appear suddenly across ...

Plaque psoriasis is the most common form ... Erythrodermic psoriasis is a rare but severe form that causes widespread, fiery ...

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Plaque psoriasis misdiagnosis is common in people of color. Learn the reasons why, how it can affect your health, and what you can do to get better care.

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...